Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.57 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.51 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17498479 | 0.85 | TMPRSS4 (0.61) | NPC1RAB9AATMMEN1KMT2A | |
| SCHEMBL14157120 | 0.82 | NPC1 (0.61) | NPC1RAB9AATMALDH1A1L3MBTL1 | |
| SCHEMBL678096 | 0.81 | PTGS1 (0.64) | GPR27TRPV4MEN1KMT2ATRPV1 | |
| SCHEMBL4823169 | 0.81 | SMN1; SMN2 (0.62) | NPC1RAB9AGPR27TRPV4ALDH1A1 | |
| SCHEMBL12334628 | 0.81 | GPR27 (0.58) | NPC1RAB9AGPR27TRPV4ALDH1A1 | |
| SCHEMBL694388 | 0.80 | CFTR (0.69) | ALDH1A1L3MBTL1CFTRKDM4E | |
| SCHEMBL12334376 | 0.80 | RORC (0.65) | NPC1RAB9AGPR27TRPV4ALDH1A1 | |
| SCHEMBL15917675 | 0.80 | NPC1 (0.52) | NPC1RAB9AATMALDH1A1MEN1 | |
| SCHEMBL15918036 | 0.80 | STAT3 (0.46) | NPC1RAB9AATMGPR27TRPV4 | |
| SCHEMBL22853165 | 0.79 | NPC1 (0.52) | NPC1RAB9AATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2951155-B1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2019-06-19 | — | — | EP | disclosed |
| US-9421196-B2 | Amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2951155-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20150328196-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-19 | — | — | US | disclosed |
| US-9108903-B2 | Amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2014120820-A9 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2014120820-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221435-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328196-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN1A, SCN5A, TRPV1 | NPC1 615/4885RAB9A 1861/4885ATM 4640/4885 |
| US-20140221435-A1 | AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN1A, SCN5A, TRPV1 | NPC1 615/4885RAB9A 1861/4885ATM 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.